GMP – Page 72 – Pharma.Tips

Manual cleaning variability during CPV review – validated efficiency improvement

Addressing Manual Cleaning Variability During CPV Review for Enhanced Efficiency Manual cleaning activities are pivotal to maintaining product quality and compliance in pharmaceutical manufacturing. However, variability during cleaning processes can…

Uncontrolled SOP changes during regulatory inspection – root cause analysis inspectors expect

Addressing Uncontrolled SOP Changes During Regulatory Inspections: A Practical Playbook Regulatory inspections can present significant challenges, particularly when uncontrolled changes to Standard Operating Procedures (SOPs) are identified. Such deviations not…

Poor change control discipline during scale-up – FDA/EMA inspection citation risk

“` Improving Change Control Integrity During Scale-Up to Mitigate Inspection Risks In the pharmaceutical industry, poor change control discipline during scale-up poses significant risks for compliance with Good Manufacturing Practices…

Inadequate GMP training during internal audit – how to rebuild GMP maturity

Addressing Inadequate GMP Training in Internal Audits to Enhance Compliance Maturity Internal audits play a critical role in ensuring compliance with Good Manufacturing Practices (GMP). However, inadequate GMP training during…

Manual cleaning variability during CPV review – cycle time reduction with compliance assurance

Addressing Manual Cleaning Variability During CPV Review for Optimal Cycle Times and Compliance In pharmaceutical manufacturing, manual cleaning processes play a critical role in ensuring product quality and compliance. However,…

Uncontrolled SOP changes during technology transfer – evidence package for inspection defense

“`html Managing Uncontrolled SOP Changes During Technology Transfer: A Playbook for Compliance Uncontrolled Standard Operating Procedure (SOP) changes during technology transfer can create significant risks for pharmaceutical manufacturers, leading to…

Inadequate GMP training during scale-up – evidence package for inspection defense

Understanding and Addressing Inadequate GMP Training During Scale-Up: An Inspection-Ready Playbook In the pharmaceutical manufacturing sector, the critical process of scale-up often highlights gaps in Good Manufacturing Practices (GMP) training.…

Poor change control discipline during regulatory inspection – how to rebuild GMP maturity

Addressing Poor Change Control Practices Pre- and Post-Inspection for GMP Compliance In the highly regulated pharmaceutical industry, poor change control discipline can lead to significant compliance issues during inspections by…

Manual cleaning variability during validation lifecycle – validated efficiency improvement

Addressing Variability in Manual Cleaning During the Validation Lifecycle In pharmaceutical manufacturing, the efficiency of manual cleaning processes is crucial to ensure product quality and compliance with GMP regulations. Variability…

Repeated GMP deviations during scale-up – FDA/EMA inspection citation risk

“`html Addressing Repeated GMP Deviations during Scale-Up to Ensure Inspection Readiness The challenge of managing repeated GMP deviations during scale-up is a critical concern for pharmaceutical manufacturers. Such deviations can…

Inadequate GMP training during technology transfer – CAPA framework to prevent recurrence

Addressing Insufficient GMP Training in Technology Transfer: A CAPA Framework Inadequate GMP training during critical technology transfer phases can significantly impair operational efficiency and compliance. This not only leads to…

Process drift not detected during regulatory inspection – how to rebuild GMP maturity

Addressing Undetected Process Drift During Regulatory Inspections: A Comprehensive Playbook In the pharmaceutical manufacturing landscape, process drift that goes undetected can lead to compliance failures, negative inspection outcomes, and potential…